Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures
-
Published:2022-07-19
Issue:12
Volume:31
Page:3501-3512
-
ISSN:0962-9343
-
Container-title:Quality of Life Research
-
language:en
-
Short-container-title:Qual Life Res
Author:
Eremenco SonyaORCID, Chen Wen-Hung, Blum Steven I., Bush Elizabeth Nicole, Bushnell Donald M., DeBusk Kendra, Gater Adam, Nelsen Linda, Coons Stephen JoelORCID,
Abstract
Abstract
Purpose
Score reproducibility is an important measurement property of fit-for-purpose patient-reported outcome (PRO) measures. It is commonly assessed via test–retest reliability, and best evaluated with a stable participant sample, which can be challenging to identify in diseases with highly variable symptoms. To provide empirical evidence comparing the retrospective (patient global impression of change [PGIC]) and current state (patient global impression of severity [PGIS]) approaches to identifying a stable subgroup for test–retest analyses, 3 PRO Consortium working groups collected data using both items as anchor measures.
Methods
The PGIS was completed on Day 1 and Day 8 + 3 for the depression and non-small cell lung cancer (NSCLC) studies, and daily for the asthma study and compared between Day 3 and 10. The PGIC was completed on the final day in each study. Scores were compared using an intraclass correlation coefficient (ICC) for participants who reported “no change” between timepoints for each anchor.
Results
ICCs using the PGIS “no change” group were higher for depression (0.84 vs. 0.74), nighttime asthma (0.95 vs. 0.53) and daytime asthma (0.86 vs. 0.68) compared to the PGIC “no change” group. ICCs were similar for NSCLC (PGIS: 0.87; PGIC: 0.85).
Conclusion
When considering anchor measures to identify a stable subgroup for test–retest reliability analyses, current state anchors perform better than retrospective anchors. Researchers should carefully consider the type of anchor selected, the time period covered, and should ensure anchor content is consistent with the target measure concept, as well as inclusion of both current and retrospective anchor measures.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference14 articles.
1. Coons, S. J., Kothari, S., Monz, B. U., & Burke, L. B. (2011). The Patient-Reported Outcome (PRO) Consortium: filling measurement gaps for PRO endpoints to support labeling claims. Clinical Pharmacology Therapeutics, 90, 743–748. 2. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Federal Register: December 9, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. [Accessed January 15, 2021] 3. Food and Drug Administration Center for Drug Evaluation and Research. FDA COA Full Qualification Package Outline. https://www.fda.gov/media/147025/download [Accessed December 17, 2021] 4. Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., Lyons, J. C., Lenderking, W. R., Hinds, P. S., Hays, R. D., Greenhalgh, J., Gershon, R., Feeny, D., Fayers, P. M., Cella, D., … Butt, Z. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research, 22, 1889–1905. https://doi.org/10.1007/s11136-012-0344-y 5. Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407–415.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|